Linical : (Delayed) FY 2023 Financial Results Briefing(1,550kb)

FY 2023 Financial Results Briefing

Wednesday, May 31, 2023

Linical Co., Ltd.

Kazuhiro Hatano, President and CEO

TSE Prime 2183

Agenda

1. Company Overview
2. Financial Results for FY ended March 2023
3. Forecasts of FY ending March 2024
4. Management Strategy
5. 1. Strengthening of Profitability
   2. Strengthening of Governance

2

Our global network

The Americas

United States★

Canada★

Preferred providers in

Latin & South America

• Office/employee locations

Current 18 countries and regions

Germany ★

United Kingdom★

Netherlands★

Czech Republic★

Spain★

Sweden★

Asia

Japan★

China★

South Korea★

Taiwan★

Singapore★

Preferred providers in

Australia

Europe

France★		Slovakia
Italy★		Portugal
Hungary★		Austria
Poland★		Belgium
Romania★		Switzerland

Preferred providers in Scandinavia, Eastern Europe & South Africa

3

The Three Businesses of Linical

• We specialize in clinical development and cover the entire process from the innovative drug development stage through to the new drug development and approval stages.

Innovative drug

development

process

Basic research	Application to	Clinical trials		Post-marketing
(2 to 3 years) to	New drug	surveillance and
start a new	phases I to III
non-clinical trials	application	clinical trials
drug trial	(3 to 7 years)
(3 to 5 years)		(4 to 10 years)

The three

businesses of

Linical

	CRO business	Contract Medical Affairs
	From 2005	From 2011
Innovative Drug
● Market analysis ● Handling of pharmaceutical affairs

Development Business● Development strategy planning ● Partnering support

From 2016

• We have developed three businesses centered on CRO business.

• Contract Medical Affairs business:	We support post-	marketing clinical research and marketing activities

• Innovative Drug Development Business :We provide consulting services that give total support for a wide range of pharmaceutical development activities including market analysis, the formulation of pharmaceutical affairs and development strategies, the selection of marketing partners, and the conclusion of contracts.

We Achieved Our Highest Ever Sales for the Second Consecutive Year

 Sales and Operating Income since Establishment (Billions of Yen)	April 2018		(Operating Profit)
	12.5	5
	Net Sales	Operating Profit			U.S. CRO Accelovance
(Net sales)			Acquisition		11.5
					November 2014		11.3	10.9	4
10
				European CRO			10.3
				Acquisition of Nuvisan	9.1
			March 2013	January 2014	8.3			3
			7.7
	October 2008	First Section of	Korea CRO P-Pro
	the Tokyo Stock	Acquisition
5	Mothers Listed	Exchange						2
				4.9			COVID-19
	June 2005
	Establishment			3.6	3.7				1
				3.1

	2.0	2.4	2.5
0.1	1.3
0.6		0

(Fiscal year) 2006/3 2007/3 2008/3 2009/3 2010/3 2011/3 2012/3 2013/3 2014/3 2015/3 2016/3 2017/3 2018/3 2019/3 2020/3 2021/3 2022/3 2023/3

We achieved our highest ever sales for the second consecutive year. Operating profit also
recovered, bringing the operating margin to a level in excess of 10%.	5